1. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.
- Author
-
Nguyen TH and Barr FG
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Combined Modality Therapy, Drug Discovery, Humans, Molecular Targeted Therapy, Rhabdomyosarcoma drug therapy, Rhabdomyosarcoma pathology, Antineoplastic Agents pharmacology, Gene Expression Regulation, Neoplastic drug effects, Oncogene Proteins, Fusion antagonists & inhibitors, Oncogene Proteins, Fusion metabolism, Paired Box Transcription Factors antagonists & inhibitors, Paired Box Transcription Factors metabolism, Rhabdomyosarcoma genetics, Rhabdomyosarcoma metabolism, Signal Transduction drug effects
- Abstract
Rhabdomyosarcoma (RMS) is a family of soft tissue cancers that are related to the skeletal muscle lineage and predominantly occur in children and young adults. A specific chromosomal translocation t(2;13)(q35;q14) that gives rise to the chimeric oncogenic transcription factor PAX3-FOXO1 has been identified as a hallmark of the aggressive alveolar subtype of RMS. PAX3-FOXO1 cooperates with additional molecular changes to promote oncogenic transformation and tumorigenesis in various human and murine models. Its expression is generally restricted to RMS tumor cells, thus providing a very specific target for therapeutic approaches for these RMS tumors. In this article, we review the recent understanding of PAX3-FOXO1 as a transcription factor in the pathogenesis of this cancer and discuss recent developments to target this oncoprotein for treatment of RMS., Competing Interests: Authors declare no conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF